期刊文献+

临床分离碳青霉烯类耐药肠杆菌科分布及其酶的表型分析 被引量:6

Distribution of clinically isolated carbapenem-resistant Enterobacteriaceae and phenotypic analysis of their enzyme
原文传递
导出
摘要 目的了解医院碳青霉烯类耐药肠杆菌科(CRE)临床分布及其酶的表型。方法采用回顾性调查方法,对某医院临床分离CRE菌株分布及其碳青霉烯类药物的耐药表型进行分析和评估。结果从住院患者送检标本中共分离到CRE 98株,其中肺炎克雷伯菌、大肠埃希菌和阴沟肠杆菌分居前3位,构成比依次为72.45%、10.20%和7.14%。m CIM试验阳性的CRE菌株90株,其中产金属β-内酰胺酶菌株26株,产丝氨酸碳青霉烯酶菌株64株。肺炎克雷伯菌中,以产丝氨酸酶表型为主(95.38%),大肠埃希菌和阴沟肠杆菌均以产金属β-内酰胺酶为主,分别占88.89%和100.00%。结论该医院临床分离CRE(头孢他啶-阿维巴坦)菌株主要为肺炎克雷伯菌;碳青霉烯酶表型以丝氨酸碳青霉烯酶为主;不同菌种的酶类型差异明显。 Objective To investigate the clinical distribution of carbapenem-resistant Enterobacteriaceae(CRE)and the phenotype of its enzymes in hospital.Methods A retrospective investigation method was used to analyze and evaluate the distribution of clinically isolated CRE strains in a hospital and their carbapenem-resistant phenotypes.Results A total of98 CRE strains were isolated from the submitted specimens of hospitalized patients.Among them,Klebsiella pneumoniae,Escherichia coli and Enterobacter cloacae were the top 3 CRE strains,and their constituent ratios were 72.45%,10.20%and 7.14%,respectively.90 CRE strains were positive for m CIM test,of which 26 strains were metal-β-lactamase-producing strains and 64 strains were serine carbapenemase-producing strains.Among Klebsiella pneumoniae,the serine carbapenase-producing strains were dominated,while both Escherichia coli and Enterobacter cloacae were mainly the metal-β-lactamase-producing phenotype,accounting for 88.89%and 100.00%,respectively.Conclusion The clinically isolated CRE(ceftazidime-avibactam)strains in this hospital are mainly Klebsiella pneumonia;the carbapenemase phenotype is mainly serine carbapenemase;the enzyme types of different strains are significantly different.
作者 李小四 范陈良 冯燕 倪侃翔 沈梦丽 李爱娟 宋国蓉 LI Xiao-si;FAN Chen-liang;FENG Yan;NI Kan-xiang;SHEN Meng-li;LI Ai-juan;SONG Guo-rong(The Second Hospital of Jiaxing,Jiaxing Zhejiang 314000;Jiaxing Maternal and Child Healh Care Hospital)
出处 《中国消毒学杂志》 CAS 2021年第5期342-344,共3页 Chinese Journal of Disinfection
基金 嘉兴市科技计划项目(2018AD32002,2018AD32001)。
关键词 肠杆菌科 碳青霉烯酶 耐药性 Enterobacteriaceae carbapenemase drug resistance
  • 相关文献

参考文献6

二级参考文献65

  • 1骆俊,朱德妹,徐晓刚,吴卫红,王明贵,张婴元,汪复.泛耐药弗劳地柠檬酸杆菌产β内酰胺酶及同源性[J].中华传染病杂志,2006,24(5):291-295. 被引量:20
  • 2Bush K. Alarming 13-1actamase-mediated resistance in multidrug-resist- ant Enterobacteriaceae[J]. Curr Opin Microbiol, 2010, 13(5) : 558 - 564.
  • 3Drawz S M, Bonomo A. Three decades of beta-lactamase inhibitors [J]. Clin Microbiol Rev, 2010, 23(1): 160 -201.
  • 4Ehmann E, Jahic H, Ross P L, et al. Avibactam is a covalent, revers- ible, non-13-1actam-lactamase inhibitor[J]. Proc Natl Acad Sci U S A, 2012, 109(29): 11663-11668.
  • 5Stachyra T, Pechereau M C, Bmnean J M, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXLI04, a novel non-beta- lactam beta-lactamase inhibitor [ J]. Antimicrob Agents Chemother, 2010, 54(12) : 5132 -5138.
  • 6Bonnefoy A, Dupuis-Hamelin C, Steier V, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-laetam beta-lacta- mase inhibitor [ J ]. J Antimierob Chemother, 2004, 54 ( 2 ) : 410 - 417.
  • 7Zhanel G G, Lawson C D, Adam H, et al. Ceftazidime-avibactam: anovel cephalosporin/13-1actamase inhibitor combination [ J ]. Drugs, 2013, 73(2) : 159 - 177.
  • 8Livermore D M, Mustaq S, Warner M, et al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lacta- mases and carbapenemases [ J ]. J- (5) : 1053 -1056. 2008, 62.
  • 9Dubreuil L J, Mahieus S, Neut C, et al. Anti-anaerobic activity of a new 13-1actamase inhibitor NXL104 in combination with J3-1actams and metronidazole [ J ]. Int J Antimierob Agents, 2012, 39 ( 6 ) : 500 - 504.
  • 10Citron D M, Tyrrell K L, Merriam V, et al. In vitro activity of ceftazi- dime-NXL104 against 396 strains of beta-lactamase-producing anaer- obes [ J ]. Antimicrob Agents Chemother, 2011,55 (7) : 3616 - 3620.

共引文献568

同被引文献45

引证文献6

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部